Abstract: This study explores the deployment of Reconfigurable Intelligent Surfaces (RISs) in a multiuser communication network. Specifically, a global optimization algorithm based on Particle Swarm ...
Hosted on MSN
'She did not accept' Kalyan Banerjee raises concerns over security changes for Mamata Banerjee
Kolkata (WB), June 18, 2026 (ANI): TMC MP Kalyan Banerjee said, "It is very unfortunate that the PSO of Mamata Banerjee who was there for 20 years has been taken away. I have been told that the the ...
Takeda (TAK) says its tyrosine kinase inhibitor, zasocitinib, significantly outperformed deucravacitinib, a rival therapy marketed by Bristol-Myers (BMY) as Sotyktu, in a late-stage trial for patients ...
Reference implementation accompanying the paper. The repository ships four sensor-placement / field-reconstruction methods that all train and evaluate on the publicly available Tokyo Polytechnic ...
May 26 – The power of North Korea’s women’s football ecosystem was demonstrated again in the final of the AFC Women’s Champions League last weekend with Naegohyang Women’s FC beating Japan’s Tokyo ...
Who do you think was the hottest president? The Social Security math just got worse for future retirees All of our submarines are missing Iran coach says US treatment at World Cup "really terrible" ...
OKLAHOMA CITY (KFOR) — International athletes are getting some training done in the big-league city ahead of the Olympics in a couple of years. As you probably know, Riversport is hosting canoe/kayak ...
Tulsa Shakespeare Company is presenting a reimagined production of “The Tempest,” set in a desolate Route 66 town in honor of the highway’s centennial. The production runs two weekends, May 14-16 and ...
† Flucto-Order Functions Research Team, RIKEN-HYU Collaboration Research Center, RIKEN Advanced Science Institute, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan ‡ Photonic Network Research Institute, ...
Takeda’s closely watched and highly valued dermatology pill zasocitinib has won out in two key phase 3 trials, giving the Japanese pharma confidence to move toward a 2026 approval filing in the U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results